Migraine Drugs Market Expected to Reach $2,190 Million, Globally, by 2025
The market was valued at $1,713 million in 2017, and is expected to reach $2,190 million by 2025, growing at a CAGR of 3.1% from 2018 to 2025. North America is anticipated to be the highest revenue contributor throughout the forecast period. The market was valued at $1,713 million in 2017, and is expected to reach $2,190 million by 2025, growing at a CAGR of 3.1% from 2018 to 2025. North America is anticipated to be the highest revenue contributor throughout the forecast period.
Segments Migraine Drugs Market
Company Profiles Migraine Drugs Market 1. Abbott Laboratories 2. AbbVie Inc. 3. Allergan Plc. 4. AstraZeneca PLC 5. Eisai Co., Ltd. 6. Endo International Plc.
- Page 1 and 2: Opportunity Analysis and Industry F
- Page 3 and 4: Introductionof Migraine Drugs Marke
- Page 5 and 6: Table of Content (TOC) Chapter: 1 I
- Page 7: Segments Migraine Drugs Market
Company Profiles<br />
<strong>Migraine</strong> <strong>Drugs</strong> <strong>Market</strong><br />
1. Abbott Labora<strong>to</strong>ries<br />
2. AbbVie Inc.<br />
3. Allergan Plc.<br />
4. AstraZeneca PLC<br />
5. Eisai Co., Ltd.<br />
6. Endo International Plc.
Change language